BridgeBio Pharma LLC announced that it has received $299.2 million in funding led by existing investors KKR & Co. Inc. (NYSE:KKR) and Viking Global Investors LP on January 23, 2019. The transaction included participation from existing investors Perceptive Advisors LLC, American International Group, Inc. (NYSE:AIG), Aisling Capital LLC, Cormorant-Capital, and Hercules Capital, Inc. (NYSE:HTGC).

The transaction also included participation from new investors Sequoia Capital and a blue-chip long-term investor.